Vaccine Conjugates Market Research Report - Forecast to 2030

Vaccine Conjugates Market Research Report: By Type (Monovalent, Multivalent), Disease Indication (Pneumococcal, Influenza, Meningococcal), Pathogen Type (Bacterial, Viral, Combination), Patient Stage (Pediatrics, Adult), End-User-Forecast to 2030

ID: MRFR/Pharma/0601-HCR | November 2022 | Region: Global | 110 Pages         

 Vaccine Conjugates Market Speak to Analyst Request a Free Sample

Vaccine Conjugates Market Overview


The vaccine conjugates market is anticipated to reach USD 17,234.8 Million by 2030 at 15.2% CAGR during the forecast period 2022-2030.
Conjugate vaccines have helped to reduce Hib and meningitis in developed and developing nations. Experts say that conjugate vaccines are very effective in immunizing bacterial meningitis for children below 2 years. Conjugated vaccines for Hib have been increasingly used in several countries for covering three doses. Further, to this report, the increase in the investment by the major companies has been under the review period. The increase in the prevalence of infectious disease within children and also the rising range in the number of all awareness programs has been to promote the driving growth of the entire market analysis.


 The market growth will be attributed to the high prevailing of infectious disease, improved efforts by the government and corporates for vaccine R & D. Since the focus on immunization has increased, capital investments have increased from the last few years.


COVID- 19 Analysis


The focus on immunization has increased due to the rapid spread of the infection. Research is ongoing which is indicates that strong immune systems are required from childhood, which further helps the individuals in fighting infectious disease. It also observed that pandemic condition is not certain, hence the end cannot be determined, due to which vaccines doses might be increased in the upcoming months as a different variant of the viruses has been observed in nations. The need for vaccine conjugatesin the upcoming years will be coupled due to the improvisation of vaccination in varied countries of the world owing to the ongoing research in COVID-19.


Vaccine Conjugates Market Dynamics


Drivers


In the upcoming years, financial support and other types of government support will help in improving the development which will foster vaccine conjugates market growth. This will further help in advancing vaccine formulas and manufacturing, thereby preventing the spread of infectious diseases.  The conditions like pandemics and rapid increase of disease will improve public and private focus for developing immunization programs.  The demand for vaccination has improved from past years for treating several types of infectious and chronic diseases which will propel vaccine conjugates market growth.


Opportunities


During the forecast period, it is estimated that investments from both the public and private sectors will increase. Owing to the increasing need for vaccination for various diseases especially corona thus providing lucrative opportunities for vaccine conjugates market growth.  Also, ongoing R&D will help in developing vaccines to combat coronavirus and its various versions which will foster vivid opportunities for enhancing vaccine conjugates market size.


Challenges


The vaccine conjugates go through a complex manufacturing process which restricts profitability with an increased cost of production. In addition to this, vaccine conjugates market share will be challenged with negative perceptions regarding fraudulent activities and the manufacturing of fake vaccines.  For example, a Chinese manufacturing company was found guilty due to the fabrication of its records in the production and distribution of vaccines.


Restraints


The minimum control of Coronavirus disease can be done through vaccinations; hence the entire region will be covered as market areas. In many developing and underdeveloped regions, the route of rural areas is still not efficiently connected with main cities. This will impact the distribution of vaccines, hence indirectly impacting the vaccine conjugate market share.  Also, several countries are engaged in the production and manufacturing of vaccines for promoting the growth of homegrown companies. Thereby, vaccine conjugates market growth in the global markets will be hindered. This restraint is further supported by international restrictions on import and export due to pandemics.


In addition to this, another situational factor that will restrict the market growth will include risks of shortage, worsening oligopoly conditions, uncertainty on futuristic initiatives, and others.


Cumulative Growth Analysis


From the year 2014, rapid growth within the vaccine conjugates market has been witnessed owing to increasing R&D in chronic disease and investments from various national and international agencies.  During the forecast period, it is estimated that conjugated vaccines for adults will be increased which is further supported with regulatory approvals. Also, markets in Asian economies will provide high vaccine conjugates market growth.


Value Chain Growth


An increase in the number of vaccine conjugates growth has given a rise in the market. Hence, this has contributed to the entire overall impact on the market positively. Also, the growing initiatives by the government for the development and research will improve the value chain of the Vaccine Conjugates Market in the forthcoming years.


Segment Overview


Additionally, the segments for vaccine conjugates market growth will include disease indication, pathogen, type, patient stage, and geography. The conjugate market and its entire market segmentation have been under the basis of the indication, type, and end-users. Thus, on all of this particular basis, the conjugate vaccine market has been segmented into adults and pediatrics. This claims the importance of the information gathered from WHO, European Society of Clinical Microbiology, U.S National Library of Medicines, and other sources.



  • By type- It is subdivided into monovalent and multivalent conjugated vaccines.

  • By disease indication- It is further categorized into pneumococcal, influenza, DTP, and meningococcal.

  • By Patient stage- It includes two subcategories that are pediatrics and adult conjugated vaccines.

  • By Pathogen Type- It is further subdivided into bacterial, viral, and combination conjugated vaccines.

  • By End-User- Pediatrics, and Adults


Regional Analysis


The vaccine conjugates market size has been subdivided into North America, Europe, Asia Pacific, and the rest of the world. On this regional basis, the conjugate vaccine market has been segmented and America appears to be considered as the largest share of the market with favorable implications to the world market. Europe has been under the second-largest position in this globe and later has been followed by Asia-Pacific. Thus, in Europe, the availability of funds for research has been under the growing emphasis that prevents the increase of the prevalence of the disease. further, Asia-pacific has the fastest growth in the conjugate market and due to it, the developing countries have been emphasized with managing decisions. thus, the developing countries within this region manage to prevent the measures for treating them. mostly, India and China have been expecting to be in an emerging position that fastens the growth of the global market. Lastly, the Middle East & Africa happen to own the lowest share in the market due to the less availability of the medical facilities of the global conjugate vaccine market.


Competitive Landscape


Key market players include Bharat Biotech (India), GlaxoSmithKline Plc (UK), Serum Institute of India, Sanofi Pasteur (France), Merck and Company (US), CSL Limited (Australia), Pfizer Inc. (US), Novartis AG (Switzerland), Neuron Biotech (the US) and Biological E (India).


Recent Development


 In the year 2018, Pfizer Inc. had received the designation in breakthrough therapy from FDA. The designation was received for 20 valent pneumococcal conjugate vaccines which will prevent pneumonia and other invasive diseases diagnosed in 18 years and above.  In the year 2016, Pfizer Inc. had received approval from European Commission for its conjugated vaccine against IMD and others. It is expected that this market player will achieve the highest growth rate due to its consignment of supplying vaccines developed for pandemics throughout many regions of the world.


Report Overview


This report mainly includes all the details and it tends to initialize the growth along with better efficiency of the market with particular management. It states that the driving factors have been interrupted due to the sudden covid 19 situations. The entire analysis is based upon the Covid 19 analysis, regional analysis, market overview, segmentation analysis, market dynamics and it mainly includes the challenges, opportunities, restraints, and drivers. Further, the competitive landscape and the other sections are presented. Hence, all of the information that has been collected is from the primary as well as the secondary sources.


By Geographically



  • North America

  • Europe

  • Asia- Pacific

  • The Middle East and Africa

  • Other regions of the world


Segmentation


By Technology



  • Conjugate Vaccines

  • Inactivated and subunit vaccines

  • Recombinant vaccines

  • Toxoid vaccines


By Type



  • Multivalent Vaccines

  • Monovalent Vaccines


By Patient type



  • Pediatric patients

  • adult patients


By Disease Indication



  • DTP

  • Polio

  • Rotavirus

  • Hepatitis

  • MMR

  • Herpes Zoster

  • Influenza


By Region




  • North America




  • Europe




  • Asia-pacific




  • Middle-East




  • Rest of the world





Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 17,234.8 Million
  CAGR   15.2% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage    Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Pathogen Type, Patient Stage, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), Medimmune, LLC (U.S.), Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Fablife. (India), SutroVax Inc. (U.S), Sinovac Biotech Ltd. (China), and others.
  Key Market Opportunities   The rising occurrence of diseases caused by microorganisms, increasing awareness about prevention of infectious diseases
  Key Market Drivers   Increasing number of regulatory approvals to the vaccines are expected to drive the growth of the market


Speak to Analyst Ask for Customization